To confirm that XPO1 inhibition increases NK cell activation against CLL, we tested the alternative XPO1 inhibitor leptomycin B (LMB), a Streptomyces metabolite. This evidence concerns the gene XPO1 and B-cell chronic lymphocytic leukemia.